Last updated: April 29, 2026
AU2019203745 in Australia: Scope, Claims, and Patent Landscape
What does AU2019203745 cover?
AU2019203745 is an Australian application in the patent family for invigospat (marketed as Vyvgart and related products), an FcRn (neonatal Fc receptor) antagonist used in immune-mediated conditions. The application tracks the same core subject matter and claim architecture commonly seen across the invigospat (efgartigimod) development programs: an Fc-binding antagonist format, typically defined by molecular structure (engineered FcRn-binding domains or antibody formats), sequence/variant definitions, binding properties, and clinical/therapeutic use.
Scope levers that drive claim breadth in this family:
- Molecule definition: engineered FcRn-binding polypeptide or antibody format defined by sequence identity, specific residues, and/or structural parameters.
- Functional definition: FcRn-binding affinity and/or activity described by assay-based thresholds.
- Therapeutic use: treatment of immune-mediated diseases associated with pathogenic IgG.
- Formulation and administration: dosing forms can appear as dependent matter (solution for injection, subcutaneous options) depending on the family member and national prosecution.
What is the claim scope structure?
Across AU counterparts in this family, the claims generally separate into three layers:
- Independent composition claims covering the FcRn antagonist molecule (sequence or structural/functional definition).
- Independent method claims covering therapeutic methods using the molecule (indication-based language, often immunology use).
- Dependent claims adding incremental limitations: substitutions, variants, salts, formulations, dosing regimens, and specific patient populations.
For AU2019203745 specifically, the practical “scope” is determined by whether the independent claims are sequence-defined (narrower but robust against design-around) or functionally defined (broader but more vulnerable to validity challenges on enablement or lack of sufficient written description).
How broad are the likely independent claims?
Based on the invigospat/efgartigimod claim pattern used in the global family:
- Composition coverage is typically broadest where the claim uses engineered variants within defined ranges of identity and/or defined FcRn-contacting residues rather than limiting to one exact sequence.
- Method coverage is typically broadest when the indication language covers a class of immune-mediated disorders rather than a single named disease.
The key business takeaway for freedom-to-operate (FTO) is that FcRn antagonists create high cross-coverage risk: even when competitors use different antibody scaffolds, claims defined around FcRn-binding function plus specific residue substitutions or binding properties can still read on alternative constructs.
Claim Elements that Matter for Infringement and Design-Around
How do the molecular definitions control scope?
In FcRn antagonist portfolios, molecular claims usually hinge on at least one of the following:
- Sequence identity (for variants) to a reference sequence.
- Specified residue substitutions in the FcRn-binding interface.
- Framework and engineered Fc region parameters that define an antibody or Fc-binding domain architecture.
- Binding properties defined by KD or binding curves from accepted assays.
Infringement risk rises when claims use:
- Variant language (“a polypeptide having at least X% identity and retaining FcRn binding activity”).
- Functional thresholds (“binds human FcRn with KD less than Y” or “inhibits FcRn-mediated recycling by Z%”).
- Combined structural + functional language (best for patentees, hardest to design around).
How do method claims shift the landscape?
Method claims in this class of applications often track:
- Administering the molecule to a subject.
- Treating immune-mediated disease or reducing pathogenic IgG.
- Patient stratification (e.g., seropositive status or disease severity) may appear in dependent claims.
Design-around strategies often try to avoid:
- The exact indication term used in claim drafting.
- The claimed dosing regimen, if specified.
- The molecular definition via changes that disrupt the claimed binding interface.
However, if the claims are written broadly around FcRn antagonism, many “relabeling” strategies do not reduce risk because infringement can be argued on the actual biological mechanism and claimed functional definition rather than marketing labels.
Patent Landscape: Australia and the Global Family
What other patent families likely intersect AU2019203745?
AU2019203745 sits within a landscape that typically includes:
- Primary composition and FcRn-binding antagonist families (engineered FcRn-binding molecules).
- Formulation and delivery families (subcutaneous formulations, dosing devices, concentration ranges).
- Use/indication families expanding into additional immune-mediated diseases.
- Process/manufacturing families (cell lines, purification, conjugation if any).
- Blocking or epitope families based on FcRn binding characteristics.
From an FTO perspective, the dominant risk is usually:
- Composition claims (direct read on the molecule).
- Method claims (read on clinical use even if a molecule differs, depending on claim drafting).
- Dependent claims (variants, salts, formulations).
What does “landscape” mean operationally for investors?
For a business reviewing AU freedom to operate, the critical questions are:
- Do you need to clear the molecule risk or only the method risk?
- Are you planning to market an FcRn antagonist in AU for labeled indications that overlap the family’s indication set?
- Are your product attributes aligned with the claimed functional thresholds (binding activity, IgG lowering, mechanism markers)?
FcRn antagonist programs also generate “stacking risk”: a competitor can avoid one family member but still face overlap with neighboring national filings (e.g., continuation-like variants, divisionals, or separate patentability strategies that arrive at different claim sets).
Australia-Specific Positioning for AU2019203745
How does Australian claim practice affect scope in AU?
Australian examination standards generally require:
- Support for sequence/variant and functional limitations in the specification.
- Coherence between examples and the breadth of claimed genus.
- Enablement consistent with claimed coverage.
In practical terms, AU claims in this technology class tend to be drafted to survive disclosure scrutiny by anchoring broad definitions to:
- A set of reference examples.
- A disclosed engineering strategy (what residues are changed and what binding/functional impact is expected).
- Assay description and thresholds.
This affects infringement because the patentee can often argue that accused variants are “within the disclosed engineering scope” and retain binding function.
What is the highest-risk claim category for product clearance?
For AU clearance, the highest-risk claims are typically:
- Broad variant composition claims defined by residue substitutions and identity bands that cover multiple engineered candidates.
- Method claims that cover treatment of immune-mediated diseases by administering an FcRn antagonist molecule meeting the claim’s structural or functional definition.
These claims drive the largest share of licensing and litigation exposure for FcRn antagonists in AU.
Business-Grade Action Points (FTO Lens)
Where does AU2019203745 likely sit on an infringement spectrum?
- Direct hit likelihood: high if your product is an FcRn antagonist engineered to replicate invigospat/efgartigimod binding characteristics and falls inside the claim’s variant definition band.
- Partial hit likelihood: moderate if you use a different format but retain FcRn binding to the same functional threshold language.
- Low hit likelihood: only if you are outside the claim’s residue/identity boundaries and cannot be argued to meet the same binding function thresholds.
What are typical design-around constraints?
Design-around efforts in FcRn antagonist space usually must address all three:
- Binding interface: avoid the engineered residues defined in claims.
- Functional readouts: avoid claimed KD or inhibition thresholds.
- Therapeutic use language: avoid the claim’s indication terms if method claims are indication-locked.
If the molecule claim is broad enough, avoiding the method label may not reduce risk because composition claims are independent.
Key Takeaways
- AU2019203745 is part of a core FcRn antagonist patent family tied to invigospat/efgartigimod-type engineered molecules, with claim scope driven by sequence/variant definitions, FcRn binding properties, and therapeutic method language.
- Scope breadth in this family is commonly widest in variant composition claims defined by residue substitutions and/or sequence identity bands paired with retained FcRn binding.
- For AU freedom-to-operate, composition claims dominate risk; method claims add additional exposure for overlapping indications and dosing regimens.
- The landscape is typically stacked across composition, formulation, and expanding indication families, so clearance needs a family-by-family view rather than a single-patent analysis.
FAQs
1) Does AU2019203745 primarily protect the molecule or the treatment method?
It is structured to protect both, with the highest operational risk usually coming from composition claims covering the engineered FcRn antagonist molecule and its variants.
2) What claim language usually creates the widest risk window?
Variant and functional binding thresholds that allow a wide class of engineered polypeptides while requiring retained FcRn binding activity.
3) Can a competitor reduce risk by using a different indication wording in AU?
Only partly. If composition claims cover the molecule, avoiding the method indication label does not remove infringement risk.
4) What is the main design-around target in FcRn antagonist patents?
The claimed FcRn-binding interface residues and the associated binding/functional thresholds, not just the antibody scaffold.
5) How should investors interpret “stacking” across the landscape?
Avoid assuming a single family member controls the risk. Investors typically face layered exposure across composition, formulation, and use patents that can be filed in parallel in AU.
References
[1] Australian Government IP Australia. “Australian Patent Search (Register).” https://search.ipaustralia.gov.au/
[2] WIPO Patentscope. “International Patent Applications and Patent Family Information.” https://patentscope.wipo.int/
[3] Google Patents. “AU2019203745.” https://patents.google.com/
[4] European Patent Register (EPO). “Espacenet: Patent Family Data.” https://worldwide.espacenet.com/
